SPC Manufacturing Waiver Regulation Will Enter Into Force On 1 July 2019

JA
J A Kemp LLP

Contributor

J A Kemp LLP logo
J A Kemp is one of the largest UK and European patent and trade mark attorney firms, with offices in London, Oxford, Cambridge, Paris and Munich.  The firm works for a huge variety of clients, from startups, spinouts and SMEs through to some of the largest corporate clients and most prestigious academic institutions in the world.
On 11 June 2019, the EU published Regulation (EU) 2019/933, which amends Regulation (EC) 469/2009 concerning supplementary protection certificates (SPCs).
European Union Consumer Protection
To print this article, all you need is to be registered or login on Mondaq.com.

On 11 June 2019, the EU published Regulation (EU) 2019/933, which amends Regulation (EC) 469/2009 concerning supplementary protection certificates (SPCs).

The amendments to the SPC regulation will permit third parties to manufacture a medicinal product protected by an SPC for the exclusive purpose of export to countries outside the EU. The amendments will also permit third parties to stockpile such a medicinal product up to six months prior to SPC expiry, for the purpose of day one release in the EU after expiry of the SPC.

The amendments will enter into force on 1 July 2019. The following transitional provisions will apply.

  • An SPC granted and in force prior to 1 July 2019: the waiver will not apply.
  • An SPC granted on an SPC application filed on or after 1 July 2019: the waiver applies.
  • An SPC granted on an SPC application filed prior to 1 July 2019, but where the SPC is not in force until on or after 1 July 2019: the waiver only applies from 2 July 2022.

In view of the above, it is advisable where possible to file new SPC applications prior to 1 July 2019.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More